The stock of Bionano Genomics Inc. (NASDAQ:BNGO) decreased by -$0.12 on Tuesday to finish at $3.34, down -3.47 percent. The last five days have seen an average of 1,461,100 shares of common stock traded. 8 times new highs were reached in the current year, with a fall of -$11.26. The average number of shares traded over the last 20 days was 1,237,232, while the average volume over the last 50 days totaled 1,178,928.
BNGO stock dropped -48.11% since last month. On 08/15/23, the company’s shares reached a one-month low of $3.27. The stock touched a high of $37.30 on 02/02/23, after rallying from a low of $3.36 in 52 weeks. The price of BNGO stock has declined by -77.12% or -$11.26 this year, reaching a new high 8 times. Still, the stock price is down -91.05% from the 52-week high.
Insider Transactions
BNGO stock investors should be aware that Bionano Genomics Inc. (BNGO) stock had its last reported insider trading activity 64 days ago on Jun 13. On Jun 13, Director Mamuszka Hannah acquired 65,789 shares at $0.76 each. This transaction resulted in the insider spending $50,000. On May 16, Holmlin R. Erik added 15,000 shares at a price of US$0.64. After the transaction, the insider now owns 806,474 shares. Chief Financial Officer Stewart Christopher P. had earlier bought 50,000 shares on May 12 for $0.67 a share. The transaction was completed for $33,415.
Valuation Metrics
Beta for the stock is 2.20. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.47, the price-to-book (PB) ratio of 0.49.
Financial Health
For the three months ended June 29, Bionano Genomics Inc.’s quick ratio was 2.70, while its current ratio was 3.70, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.02, and the total debt to equity ratio is 0.02. As far as profitability goes, gross margin for the trailing twelve months is 24.20% percent. Based on annual data, it had gross profit of $5.95 million and revenue of $27.8 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BNGO’s return on assets (ROA) during the last 12 months has been -49.10%. There was a -52.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -60.00%.
Earnings Surprise
According to Bionano Genomics Inc.’s quarterly financial report for the quarter that ended June 29, it had $62.21 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $8.66 million, while revenues rose by 22.98% to $7.42 million. It was predicted that Bionano Genomics Inc.’s quarterly earnings would be -$1.24, but it ended up being -$1.03, beating the consensus by -20.40%. EBITDA was -$36.03 million for the quarter. At the end of Bionano Genomics Inc.’s most recent quarter ended June 29, its liabilities totaled 56.62 million, while its total debt was $10.66 million. Equity owned by shareholders amounts to $35.35 million.
Technical Picture
Here’s a quick look at Bionano Genomics Inc.’s (BNGO) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 15.58%, suggesting the stock is oversold, with a 102.73% historical volatility rate.
The stochastic %K and %D were 6.21% and 9.83% respectively, while the average true range (ATR) was 0.44. Based on the 14-day stochastic reading of 2.40%, the RSI (14) reading is 20.75%. On the 9-day MACD Oscillator, the stock is at -0.67, and the 14-day reading is at -1.23.
Analyst Ratings
In its analyst report released on January 05, 2023, Scotiabank began covering Bionano Genomics Inc. (NASDAQ: BNGO). The stock was rated as a Sector outperform by the brokerage firm. Analysts have assigned Bionano Genomics Inc. (BNGO) an Buy rating. BNGO is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is BNGO’s price target for the next 12 months?
The current consensus forecast for the stock is between $9.00 and $32.00, with a median target price of $18.75. In analyzing these forecasts, the average price target given by analysts for Bionano Genomics Inc. (BNGO) is $19.75.
